The present invention provides novel, substituted 1,5-naphthyridine azolinonesof formula (I) which inhibit Cdkl and are selective against Cdk2 and Cdk4. Thesecompounds and their pharmaceutically acceptable salts have antiproliferativeactivity and are useful as anti-cancer agents.